Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24672517 | 0.91 | KISS1R (0.37) | KISS1RHTR1BALDH1A1HRH1HTR2A | |
| SCHEMBL23806694 | 0.89 | KISS1R (0.36) | KISS1RHTR1BALDH1A1HRH1HTR2A | |
| SCHEMBL23568411 | 0.87 | LMNA (0.36) | KISS1RHTR1BALDH1A1HRH1HTR2A | |
| SCHEMBL9945675 | 0.86 | ALDH1A1 (0.36) | KISS1RHTR1BALDH1A1TDP1CA12 | |
| SCHEMBL23696017 | 0.84 | MEN1 (0.38) | KISS1RHTR1BALDH1A1TDP1CA12 | |
| SCHEMBL22790642 | 0.84 | MEN1 (0.38) | KISS1RHTR1BALDH1A1TDP1CA12 | |
| SCHEMBL20813179 | 0.84 | MEN1 (0.38) | KISS1RHTR1BALDH1A1TDP1CA12 | |
| SCHEMBL13311637 | 0.84 | MEN1 (0.38) | KISS1RHTR1BALDH1A1TDP1CA12 | |
| SCHEMBL21106870 | 0.83 | EPHX1 (0.39) | KISS1RHTR1BHRH1HTR2AEPHX1 | |
| SCHEMBL8352992 | 0.83 | HTR1B (0.46) | HTR1BALDH1A1HRH1EPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109944-A1 | TLR MODULATOR AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20210388196-A1 | GENE DELIVERY CARRIER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| US-20190194390-A1 | AMINO-POLYESTERS FOR DRUG DELIVERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2019-06-27 | — | — | US | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | KISS1R 2381/4885HTR1B 1703/4885ALDH1A1 2664/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | KISS1R 2381/4885HTR1B 1703/4885ALDH1A1 2664/4885 |
| US-20210388196-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | KISS1R 4437/4885HTR1B 4681/4885ALDH1A1 2765/4885 |
| US-20190194390-A1 | AMINO-POLYESTERS FOR DRUG DELIVERY | DNPEP, NPEPPS, ANPEP | KISS1R 3408/4885HTR1B 3061/4885ALDH1A1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.